Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 2.35 -7.11% -0.18
CLBS closed down 7.11 percent on Friday, August 16, 2019, on 72 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CLBS trend table...

Date Alert Name Type % Chg
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -7.11%
Lower Bollinger Band Touch Weakness -7.11%
Oversold Stochastic Weakness -7.11%
Oversold Stochastic Weakness -9.96%
50 DMA Resistance Bearish -11.65%
Earnings Movers Other -11.65%
Inside Day Range Contraction -11.65%

Older signals for CLBS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Banking Biopharmaceutical Cancer Diabetes Immunotherapy Cancer Immunotherapy Metastatic Melanoma Clinical Services Acute Myocardial Infarction Treatment Of Metastatic Melanoma
Is CLBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.83
52 Week Low 2.16
Average Volume 49,897
200-Day Moving Average 3.6854
50-Day Moving Average 2.699
20-Day Moving Average 2.7473
10-Day Moving Average 2.611
Average True Range 0.1868
ADX 22.85
+DI 10.506
-DI 27.0012
Chandelier Exit (Long, 3 ATRs ) 2.6396
Chandelier Exit (Short, 3 ATRs ) 2.9004
Upper Bollinger Band 3.0912
Lower Bollinger Band 2.4034
Percent B (%b) -0.08
BandWidth 25.035489
MACD Line -0.0715
MACD Signal Line -0.0274
MACD Histogram -0.0441
Fundamentals Value
Market Cap 22.15 Million
Num Shares 9.43 Million
EPS -11.27
Price-to-Earnings (P/E) Ratio -0.21
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.62
Resistance 3 (R3) 2.65 2.58 2.58
Resistance 2 (R2) 2.58 2.51 2.57 2.56
Resistance 1 (R1) 2.47 2.47 2.44 2.44 2.54
Pivot Point 2.40 2.40 2.39 2.39 2.40
Support 1 (S1) 2.29 2.33 2.26 2.26 2.16
Support 2 (S2) 2.22 2.29 2.21 2.14
Support 3 (S3) 2.11 2.22 2.13
Support 4 (S4) 2.08